Catalyst’s scientists focus on creating improved, next-generation, pro-coagulant proteases and novel proteases that cleave targets in the complement cascade

We have a versatile protease engineering platform that feeds our research and development pipeline. Currently, we are focused on advancing and extending our Hemostasis and Complement product candidates. One of our key competitive advantages is that our systemically dosed product candidates, due to the improvements we have made using our protease engineering platform, can be delivered subcutaneously (“SQ”) which is less invasive, more convenient and more efficacious than intravenous (“IV”) drugs currently on the market. Our SQ product candidates demonstrate prolonged duration of activity enabling them to provide continuous therapeutic levels.